Krystal Biotech reports KB113 lesion regression in Gorlin syndrome pilot study as FDA discussions begin
Krystal Biotech, Inc. (NASDAQ:KRYS) reported preliminary clinical findings from a pilot study of KB113, an investigational ...
Model output · Signal date 2026-10-16
Krystal Biotech, Inc. (KRYS) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
Total
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Middle 30%
of 5184 stocks scored
Rank correlation · 90D
18.0%
Spearman, 357 dates
Market Cap
$9.37B
mid-cap · #16 of 60 peers
Summary
Krystal Biotech, Inc. (KRYS) stock forecast summary
On Oct. 16, 2026, KRYS is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
Krystal Biotech, Inc. is a mid-cap company with a market capitalization of $9.37B. It ranks number 16 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its Net Margin of 54.8% is the highest of the 37 peers that report one.
For KRYS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -4.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, KRYS included.
Follow KRYS freePrice
KRYS price chart and AI forecast
Cross-section · 2026-10-16
How KRYS ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Krystal Biotech, Inc. (KRYS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | KRYS | Rank |
|---|---|---|
| Market Cap | $9.37B | 16/60 |
| P/E Ratio | 39.72x | 5/15 |
| P/B Ratio | 6.89x | 17/49 |
| EPS | $7.97 | – |
| Book Value/Share | $45.92 | – |
| Revenue/Share | $14.88 | – |
| FCF/Share | $8.71 | – |
Profitability & Margins
| Metric | KRYS | Rank |
|---|---|---|
| ROE | 17.8% | 9/47 |
| ROA | 16.1% | 6/50 |
| ROIC | 14.4% | 10/53 |
| Operating Margin | 44.9% | 2/40 |
| Net Margin | 54.8% | 1/37 |
| EBT Margin | 51.5% | 1/42 |
| Tax Rate | -6.5% | – |
Financial Health
| Metric | KRYS | Rank |
|---|---|---|
| Current Ratio | 8.32x | 21/59 |
| Quick Ratio | 7.96x | 3/28 |
| D/E Ratio | 0.10x | 47/53 |
| Financial Leverage | 1.10x | 46/52 |
| Working Capital | $932M | 14/59 |
Cash Flow
| Metric | KRYS | Rank |
|---|---|---|
| Operating Cash Flow | $272M | 12/57 |
| Free Cash Flow | $258M | 11/50 |
| Capital Spending | -$15M | 35/50 |
| OCF Growth YoY | 39.4% | 8/16 |
| FCF Growth YoY | 39.0% | 6/15 |
| FCF/Sales | 58.5% | 2/32 |
| CapEx/Sales | 3.3% | 17/32 |
Operational Efficiency
| Metric | KRYS | Rank |
|---|---|---|
| Asset Turnover | 0.29x | 21/36 |
| Receivables Turnover | 3.2x | 21/24 |
| Fixed Assets Turnover | 2.9x | 24/37 |
| Days Sales Outstanding | 115 days | 3/24 |
Income Statement
| Metric | KRYS | Rank |
|---|---|---|
| Total Revenue | $440M | 16/37 |
| Operating Income | $198M | 11/54 |
| Net Income | $241M | 9/50 |
| R&D Expense | $59M | 50/56 |
| SG&A Expense | $160M | 18/22 |
Dividend & Shareholder Information
| Metric | KRYS | Rank |
|---|---|---|
| Shares Outstanding | 30M | – |
| Net Income Growth | 64.6% | 5/12 |
| EPS Growth | 60.7% | 4/14 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.06B | 70.6% of assets |
| Cash & Short-term Investments | $428M | 28.5% of assets |
| Accounts Receivable | $139M | 9.2% of assets |
| Inventory | $46M | 3.0% of assets |
| Total Liabilities | $142M | 9.4% of assets |
| Short-term Debt | $121M | 8.0% of assets |
Quarterly Financial Reports
KRYS quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Krystal Biotech, Inc. (KRYS) industry peers
Companies classified under the same SEC industry code as Krystal Biotech, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| KRYS Krystal Biotech, Inc. | ▶ | $9.37B |
| AMGN Amgen Inc | ▼ | $233.82B |
| GILD Gilead Sciences, Inc. | ▶ | $193.67B |
| MRNA Moderna, Inc. | ▲ | $87.04B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $38.14B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| BNTX Biontech Se | ▲ | $22.18B |
| EXEL Exelixis, Inc. | ▼ | $15.42B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.79B |
| TECH Bio-Techne Corp | ▼ | $11.38B |
| QGEN Qiagen N.V. | ▶ | $10.01B |
| RGEN Repligen Corp | ▲ | $9.90B |
| IBRX Immunitybio, Inc. | ▲ | $9.73B |
| PCVX Vaxcyte, Inc. | ▲ | $9.47B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.71B |
| TWST Twist Bioscience Corp | ▲ | $8.32B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.17B |
| IMVT Immunovant, Inc. | ▲ | $5.52B |
| KOD Kodiak Sciences Inc. | ▲ | $5.39B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.86B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.57B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $2.99B |
| DNLI Denali Therapeutics Inc. | ▶ | $2.81B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| LIFE Atyr Pharma Inc | ▲ | $2.37B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.07B |
| VCEL Vericel Corp | ▶ | $2.05B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| NVAX Novavax Inc | ▲ | $1.86B |
| ALVO Alvotech | ▲ | $1.78B |
| MESO Mesoblast Ltd | ▶ | $1.70B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.69B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▼ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.18B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.02B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $902M |
| MGTX Meiragtx Holdings Plc | ▶ | $891M |
| SLBT Sl Science Holding Ltd | ▶ | $873M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $825M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| SANA Sana Biotechnology, Inc. | ▲ | $680M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| PRME Prime Medicine, Inc. | ▲ | $629M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $593M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
| VALN Valneva Se | ▼ | $521M |
Where KRYS sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Krystal Biotech, Inc. (KRYS) stock news
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113Substantial regression was ...
Krystal Biotech reports over 80% lesion reduction in rare skin cancer trial
Krystal Biotech Inc. KRYS on Thursday released a clinical update for its intratumoral immunotherapy, KB113. The treatment ...
FAQ
Krystal Biotech, Inc. (KRYS) stock forecast FAQ
What is the Krystal Biotech, Inc. (KRYS) stock forecast?
On Oct. 16, 2026, KRYS is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
How accurate are Krystal Biotech, Inc. stock predictions?
For KRYS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -4.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Krystal Biotech, Inc. forecasts updated?
Krystal Biotech, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Krystal Biotech, Inc.'s industry peers?
60 issuers in our coverage, KRYS included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.